MRNA241101P52000
- 0.20
- 0.000.00%
Moderna Newsroom
Moderna to Present at Upcoming Conferences in November 2024
Is Moderna, Inc. (MRNA) The Worst Performing S&P 500 Stock In 2024?
WHO Expands Emergency Use List For Mpox Diagnostics, Adds Cepheid's Xpert Mpox PCR Test And Roche's Cobas MPXV Assay As PCR-Based Gold Standard Options
Novocure Appoints Moderna's Exec Christoph Brackmann as CFO
GSK Dips as Lower Vaccine Sales Weigh on Q3 2024 Results
Moderna (MRNA) Exceeds Market Returns: Some Facts to Consider
Recorrido Por La Ruta De La Seda De Pekín: Una Ventana a Una Metrópolis Moderna
Behind the Scenes of Moderna's Latest Options Trends
Express News | Blackrock (BLK.N) CEO Fink, Blackstone Group (BX.N) CEO Schwarzman, moderna (MRNA.O) CEO Stéphane Bancel attended the Riyadh FII conference.
Express News | BlackRock CEO Larry Fink, Blackstone CEO Stephen Schwarzman, Moderna CEO Stephane Bancel Attend Fii Conference in Riyadh
Moderna Shares Are Trading Higher After the Company Announced the Initiation of INTerpath-009 in Combination With KEYTRUDA as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB Non-small Cell Lung Cancer Who Did Not Achieve a...
Evercore Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $60
Moderna Stock Price Target Slashed. It's About Vaccines. -- Barrons.com
Express News | Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (Mrna-4157) in Combination With Keytruda® (Pembrolizumab) After Neoadjuvant Keytruda and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (Nsclc)
It's Time to Get Your Covid and Flu Shots. Everything to Know About This Year's Vaccines. -- Barrons.com
UBS Maintains Moderna(MRNA.US) With Buy Rating, Cuts Target Price to $108
Moderna Named a Top Employer by Science for Tenth Consecutive Year
Moderna Is Maintained at Buy by UBS
Moderna Analyst Ratings
Express News | Moderna Inc : UBS Cuts Target Price to $108 From $140